Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705426 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2PKMTSHRHPGDALDH1A1 | |
| SCHEMBL17992238 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2PKMTSHRHPGDALDH1A1 | |
| SCHEMBL4100352 | 0.71 | ALDH1A1 (0.33) | SMN1; SMN2TSHRALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL4099177 | 0.71 | SMN1; SMN2 (0.42) | SMN1; SMN2PKMTSHRHPGDALDH1A1 | |
| SCHEMBL16900345 | 0.68 | SMN1; SMN2 (0.48) | SMN1; SMN2PKMTSHRHPGDALDH1A1 | |
| SCHEMBL4162536 | 0.68 | SMN1; SMN2 (0.36) | SMN1; SMN2PKMTSHRHPGDALDH1A1 | |
| SCHEMBL7736774 | 0.66 | SMN1; SMN2 (0.39) | SMN1; SMN2PKMTSHRALDH1A1KDM4E | |
| SCHEMBL24894937 | 0.64 | SMN1; SMN2 (0.44) | SMN1; SMN2PKMTSHRHPGDALDH1A1 | |
| SCHEMBL3443348 | 0.64 | SMN1; SMN2 (0.47) | SMN1; SMN2PKMTSHRHPGDALDH1A1 | |
| SCHEMBL12216989 | 0.63 | ALDH1A1 (0.45) | SMN1; SMN2PKMTSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884519-B1 | METAL HYDRIDE COMPLEX, METHOD OF HYDROGENATING RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN, AND PROCESS FOR PRODUCING PRODUCT OF HYDROGENATION OF RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | JSR CORP (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20090176950-A1 | METAL HYDRIDE COMPLEX, METHOD OF HYDROGENATING RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN, AND PROCESS FOR PRODUCING PRODUCT OF HYDROGENATION OF RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | JSR CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1884519-A1 | METAL HYDRIDE COMPLEX, METHOD OF HYDROGENATING RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN, AND PROCESS FOR PRODUCING PRODUCT OF HYDROGENATION OF RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | JSR Corporation (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176950-A1 | METAL HYDRIDE COMPLEX, METHOD OF HYDROGENATING RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN, AND PROCESS FOR PRODUCING PRODUCT OF HYDROGENATION OF RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN | HPD, HMOX2, HAO2 | SMN1; SMN2 4533/4885PKM 2562/4885TSHR 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.